More and more research indicates that GLP-1 analogues can have a blunting effect on addictions like drugs and alcohol. Drug ...

DelveInsight's Parkinson's Disease Pipeline report depicts a robust space with 130+ active players working to develop 150+ ...

These receptors and the cells that express them mediate opposite approach/avoidance responses, and are differentially impacted by dopamine transmission in that region of the brain.

The most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson’s ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h ...

Dopamine agonists, although considered the first-line agents in management of moderate-to-severe RLS, are not without adverse effects, the most common being nausea, dizziness, ...

Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors — has been linked to side effects including sleep disorders, hallucinations, impulse ...

Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors — has been linked to side effects including sleep disorders, hallucinations, impulse ...

When dopamine binds to D1 receptors, it helps enhance signal processing in areas of the brain crucial for focus and attention. On the other hand, D2 receptors are more involved in modulating the ...